These findings suggest that the inhibition of MKK3-MYC interaction itself and its downstream-activated genes EIF5A, EIF5AL1, and SNAI1 may provide new therapeutic options for African American patients with triple-negative breast cancer. This evidence concerns the gene MAP2K3 and triple-negative breast carcinoma.